natgillin/translations-raw huggingface dataset:
SoliCol D3-tabletter med 20.000 IE og SoliCol D3-tabletter med 50.000 IE er lægemidler, der indeholder 20.000 eller 50.000 IE colecalciferol (vitamin D3-analog) som aktivt stof.
SoliCol D3 20,000 IU tablets and SoliCol D3 50,000 IU tablets are medicinal products containing 20,000 or 50000 IU colecalciferol (vitamin D3 analogue) as active substance.
Dutasteride Actavis er indiceret til behandling af benign prostataforstørrelse og blev første gang godkendt i EU den 3. juni 2015 gennem en decentral procedure med Danmark som referencemedlemsstat.
Dutasteride Actavis is indicated for the treatment of the benign prostatic hyperplasia and was first approved in the EU on 3 June 2015 via a decentralised procedure, with Denmark acting as Reference Member State.
De ekstra risici, som skyldes manglende overholdelse af god fremstillingspraksis, kan potentielt føre til krydskontaminering med andre lægemidler, der fremstilles på stedet, herunder hormoner, cytotoksiske midler og teratogene stoffer.
The additional risks due to non-compliance to GMP can potentially lead to potential cross-contamination with other drugs produced at the site, including hormones, cytotoxics and teratogens.
• Kritiske mangler i form af manglende organisatoriske og tekniske tiltag til minimering af risikoen for krydskontaminering mellem farlige og ikkefarlige produkter, der fremstilles på det samme anlæg og med det samme udstyr, samt kvalitetsenhedens mangelfulde sikring af kvalitetssikringssystemets funktion;
• Critical deficiencies relating to the failure of organisational and technical measures to minimise the risk of cross-contamination between hazardous and non-hazardous products manufactured in the same manufacturing facilities using shared equipment, as well as failures of the quality unit to ensure the effective operation of the quality system;
Dutasteride Actavis er et lægemiddel, der indeholder det aktive stof dutasterid, en tredobbelt 5αreduktase-hæmmer.
Dutasteride Actavis is a medicinal product containing the active substance dutasteride, a triple 5αreductase inhibitor.
Ammonaps er et centralt godkendt lægemiddel, der indeholder det aktive stof natriumphenylbutyrat.
Ammonaps is a centrally authorised product containing the active substance sodium phenylbutyrate.
Ingen kommercielle batcher af lægemidlet er fremstillet hos PII eller frigivet på EU's marked.
No commercial batches of the product have been manufactured by PII, nor released in the EU market.
Det er også fastsat, at lægemidlet skal testes yderligere efter importen til EU, idet der inden frigivelsen skal genereres et nyt sæt analyseresultater.
Further testing of the product on importation in the EU was also put in place with a new set of analytical results being generated prior to the release.
• CHMP har gennemgået tilsynsmyndighedens inspektionsrapport, (med)rapportørens vurderingsrapport og de tilgængelige data, som markedsføringsindehaverne har indsendt skriftligt som svar på CHMP's spørgsmål
• The CHMP reviewed the inspection report provided by the Supervisory Authority, the (co-) rapporteur's assessment reports and the available data presented by the MAHs in writing in response to questions addressed by the CHMP;
Tiltagene omfatter involvering af erfarne eksterne specialister i kvalitetsstyring, og at den sagkyndige person skal sikre bedre kontrol af batchdokumenterne på det sted i EØS, der er ansvarlig for batchfrigivelse.
These measures include the use of assistance from experienced external specialists specialised in Quality management and an enhanced control of the batch documents by the Qualified Person at the EEA site responsible for batch release.
Et lægemiddel kan anses for at være kritisk nødvendigt, hvis det vurderes, at der foreligger et uopfyldt medicinsk behov, idet der skal tages højde for tilgængeligheden af andre egnede lægemidler i den pågældende medlemsstat samt, hvis det er relevant, arten af den sygdom, der skal behandles.
A medicinal product may be considered critical based on the evaluation of the potential unmet medical need, considering the availability of suitable alternative medicinal products in the respective Member State(s) and, as appropriate, the nature of the disease to be treated.
Lutinus (og relaterede navne)
Lutinus (and associated names)
Derudover skal patienterne have livslang behandling, og de øvrige tilgængelige behandlingsmuligheder synes at være begrænsede, da forsyningen af alternative lægemidler kan være problematisk, og da nogle af disse ikke kan administreres gennem næsesonder/gastrostomisonder, hvilket ofte er nødvendigt hos disse patienter.
Further, patients need life-long treatment and other available treatment options appear limited, because of concerns over the supply of alternatives and the fact that some of these cannot be administered via naso-gastric/gastrostomy tubes, which is often needed in these patients.
• Alvorlige mangler i form af mangelfuld organisatorisk dataforvaltning, mangelfulde sterilisations- og depyrogeneringsprocesser og utilstrækkelig kontrol af aseptiske procedurer til opnåelse af det påkrævede sterilitetssikringsniveau.
• Major deficiencies relating to organisational data governance failures, sterilisation and depyrogenation processes, and insufficient control of aseptic operations to provide the required level of sterility assurance.
En grundig gennemgang af kumulative sikkerhedsdata om Lutinus frem til 31. maj 2016 gav heller ikke anledning til væsentlige sikkerhedsmæssige betænkeligheder relateret til manglende opfyldelse af god fremstillingspraksis.
A detailed assessment of cumulative safety data on Lutinus up to 31 May 2016 was also performed which did not raise any significant safety concerns related to GMP non-compliance.
På baggrund af sygdommens art og det forhold, at alternative behandlinger ikke er tilgængelige i alle medlemsstater, anser CHMP produktet Ammonaps for at være kritisk nødvendigt.
Based on the nature of the disease and the fact that therapeutic alternatives are not available in all Member States, the CHMP considers the product Ammonaps to be critical.
Ved en grundig gennemgang af alle markedsføringstilladelsesindehaverens indberetninger om produktklager fra de seneste 5 år fandt man ingen klager, der kunne forbindes med krydskontaminering.
A detailed assessment of all product complaint reports over the past 5 years provided by the MAH did not reveal any product complaint that could be associated to potential cross contamination.
Pharmaceutics International Inc. (PII), der har hovedsæde i Maryland, USA, er anført som fremstiller i markedsføringstilladelsen for fire lægemidler, der er godkendt i EU; det drejer sig om det centralt godkendte lægemiddel Ammonaps og de tre nationalt godkendte lægemidler Lutinus, Dutasteride Actavis og SoliCol D3.
Pharmaceutics International Inc. (PII), located in Maryland, USA is listed as manufacturer in the marketing authorisation of four products authorised in the EU, including the centrally approved product Ammonaps and three nationally approved products: Lutinus, Dutasteride Actavis and SoliCol D3.
I overensstemmelse med denne erklæring om non-compliance skal den nationale tilsynsmyndighed vurdere den kritiske nødvendighed af produkter, der leveres af PII og træffe foranstaltninger for at sikre fortsat levering, hvis det er nødvendigt.
According to this statement of non-compliance, the NCA should evaluate the criticality of products being supplied by PII and enact measures to ensure continued supply where appropriate.
Den 17. juni 2016 indledte Europa-Kommissionen en indbringelsesprocedure i henhold til artikel 31 i direktiv 2001/83/EF og anmodede Det Europæiske Lægemiddelagentur om at vurdere, hvilken betydning manglerne kunne have for kvaliteten, sikkerheden og benefit/risk-forholdet for de lægemidler, der er godkendt af Europa-Kommissionen og medlemsstaterne.
On 17 June 2016, the European Commission (EC) initiated a referral procedure under Article 31 of Directive 2001/83/EC, and requested the Agency to assess the potential impact of the deficiencies on the quality, safety and the benefit risk balance of the medicinal products which have been authorised by the European Commission and the Member States.
Erklæringen om GMP-non-compliance for PII gør det klart, at indehaverne af markedsføringstilladelsen anmodes om at kontakte den pågældende kompetente nationale myndighed for at undersøge, om deres produkter anses for at være en medicinsk nødvendighed for den offentlige sundhed i deres territorium.
The statement of noncompliance with GMP of PII clarifies that marketing authorisation holders are requested to contact the relevant National Competent Authority (NCA) to verify whether their products are considered medically critical to public health in their territory.
• CHMP henviser til proceduren i artikel 31 i direktiv 2001/83/EF, for så vidt angår lægemidler, hvor Pharmaceutics International Inc, Maryland, USA, står anført som fremstillingssted i markedsføringstilladelsen
• The CHMP considered the procedure under Article 31 of Directive 2001/83/EC for medicinal products for which Pharmaceutics International Inc, Maryland, USA, is included in the marketing authorisation as manufacturing site;
Da alle medlemsstaterne i øjeblikket får Lutinus-forsyninger, der er fremstillet på det nye fremstillingssted, forventes der ikke at blive mangel på lægemidlet.
Given that all EU Member States are currently supplied with Lutinus manufactured at the alternative manufacturing site, no shortage is foreseen for this product.
Ammonaps bør dog ikke anvendes, hvis det er muligt at give patienten en anden, egnet behandling.
In addition, Ammonaps should not be used if an alternative treatment option is available and appropriate for the patient.
Ved en fælles inspektion foretaget af den britiske lægemiddelstyrelse (MHRA) og det amerikanske kontor for kontrol med fødevarer og medicin (FDA) i februar 2016 blev der fundet kritiske og alvorlige mangler, og det blev konkluderet, at PII ikke opfyldte de lovkrav og/eller de principper og retningslinjer for god fremstillingspraksis (GMP - Good Manufacturing Practice), som EU-retten foreskriver.
In February 2016, a joint inspection by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) found critical and major deficiencies and concluded that PII was non-compliant with the legal requirements and/or the principles and guidelines of Good Manufacturing Practice (GMP) as provided for by Union law.
• Der er ikke registreret andre fremstillingssteder i markedsføringstilladelsen for SoliCol D3, og CHMP noterer, at der i øjeblikket ikke er nogen batcher af SoliCol D3 på EU's marked
• There is no alternative manufacturing site registered in the marketing authorisation for SoliCol D3 and the CHMP noted that no batches of SoliCol D3 are currently available on the EU market;
Der er ikke registreret en anden fremstiller i markedsføringstilladelsen for SoliCol D3.
No alternative manufacturer is registered in the marketing authorisation of SoliCol D3.
Alle de Dutasteride Actavis-midler, der i øjeblikket er tilgængelige på EU's marked, er fremstillet på et andet fremstillingssted, som allerede var registreret i markedsføringstilladelsen på tidspunktet for godkendelse.
All medicinal products Dutasteride Actavis currently available on the EU market were manufactured at an alternative manufacturing site already registered in the marketing authorisation at time of approval.
I betragtning af, at der ikke foreligger rapporter om krydskontaminering, at lægemidlet er kritisk nødvendigt, og at der er sket forbedringer i fremstillingen, der har nedsat risikoen for krydskontaminering, anbefales det, at leverancerne af Ammonaps fra PII til den patientpopulation, som ikke har andre behandlingsmuligheder, bibeholdes.
Given the absence of reports of cross-contamination and taking into consideration the criticality of the product and the improvements in manufacturing which has reduced the risk of cross-contamination to low, it is recommended that the supply of Ammonaps from PII is maintained for the patient population for whom no other treatment option is available.
Sikkerhedsprofilen for Ammonaps ved forstyrrelser i urinstofcyklussen er velkendt.
The safety profile of Ammonaps in urea cycle disorders is well established.
• CHMP noterer, at der ikke er nogen batcher af Dutasteride Actavis fra Pharmaceutics International Inc. på EU's marked
• The CHMP noted that there are no batches of Dutasteride Actavis from Pharmaceutics international Inc. on the EU market.
Dutasteride Actavis (og relaterede navne)
Dutasteride Actavis (and associated names)
Dutasteride (og relaterede navne)
Dutasteride (and associated names)
Det er indiceret til behandling af patienter med forstyrrelser i urinstofcyklussen, som involverer mangel på karbamylfosfatsyntetase, ornithintranskarbamylase eller argininosuccinatsyntetase.
It is indicated to treat the patients who have urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.
GMP-certifikatet er gyldigt indtil den 30. juni 2017.
This certificate of GMP compliance is valid until 30 June 2017.
Der er ikke rapporteret om krydskontaminering efter markedsføringen, men i betragtning af, at der er tale om en alvorligt syg og meget lille patientpopulation (da forekomsten af sygdommen er meget lav), giver fraværet af indberetninger kun begrænset dokumentation for sikkerheden.
Although no reports of cross-contamination have been reported in the post-marketing setting, taking into account the target population, that is severely ill and the small patient population (as the prevalence of the condition is very low), the lack of such reports only provides a low degree of reassurance.
CHMP anbefaler desuden, at der snarligt sendes breve ud til sundhedspersoner for at gøre opmærksom på resultatet af denne gennemgang og konklusionerne med hensyn til anvendelsen af Ammonaps.
Furthermore, the CHMP recommended that in due course, appropriate communications should be issued and proposed Direct Healthcare Professional Communications (DHPC) to inform on the outcome of the review and the conclusions reached concerning the use of Ammonaps.
• CHMP har noteret, at batcher af Lutinus fra Pharmaceutics international Inc. i øjeblikket kan fås på EU's marked
• The CHMP noted that batches of Lutinus from Pharmaceutics international Inc. are currently available on the EU market.
Lægemidlet er endnu ikke markedsført, og indehaveren af markedsføringstilladelsen har bekræftet, at ingen kommercielle batcher af lægemidlet er fremstillet hos PII.
The product has not yet been launched on the market and the MAH confirmed that no commercial batches of the product had been manufactured at PII.
Den gavnlige effekt af Ammonaps i den godkendte indikation, forstyrrelser i urinstofcyklussen, er almindeligt anerkendt.
The benefits of Ammonaps in its approved indication of urea cycle disorders are well established.
• Der er ikke registreret andre fremstillingssteder i markedsføringstilladelsen for Ammonaps
• There is no alternative manufacturing site registered in the marketing authorisation of Ammonaps;
Udover ovennævnte konklusioner bemærkede CHMP, at tilsynsmyndighederne i erklæringen om GMPnon-compliance for PII anbefaler, at alle batcher af Lutinus fra Pharmaceutics Internationals Inc. trækkes tilbage, og at der nedlægges leveringsforbud.
In addition to the above conclusions, the CHMP noted the recommendations from the Supervisory Authority in the statement of non-compliance with GMP of PII that all batches of Lutinus from Pharmaceutics Internationals Inc. should be recalled and the supply from this manufacturing site prohibited.
• Lutinus bliver i øjeblikket fremstillet på et andet fremstillingssted, der er registreret i markedsføringstilladelsen
• Lutinus is currently manufactured at an alternative manufacturing site registered in their marketing authorisation;
MHRA har udstedt et tilsvarende GMP-certifikat for PII, der kun omfatter lægemidler, som de nationale kompetente myndigheder vurderer er af afgørende betydning for den offentlige sundhed.
The MHRA issued a corresponding certificate of GMP compliance for the site, limited to medicinal products confirmed by National Competent Authorities as being critical to public health.
Den 15. juni 2016 udstedte MHRA en erklæring om GMP-non-compliance (manglende overholdelse af retningslinjerne for god fremstillingspraksis) for PII, hvori det anbefales, at der iværksættes restriktioner for leverancerne i EU, og at de lægemidler, der er fremstillet på det omtalte fremstillingssted, trækkes tilbage, medmindre de vurderes at være af afgørende betydning for den offentlige sundhed.
On 15th June 2016 the MHRA issued a GMP Statement of Non-Compliance (SNC) for PII, recommending a restriction of supply in the EU and the recall of the medicinal products manufactured at this site unless considered critical to public health.
• I betragtning af sygdommens art og de manglende alternativer i alle medlemsstater, vurderer CHMP, at Ammonaps er kritisk nødvendigt for den offentlige sundhed CHMP vurderer således, at benefit/risk-forholdet for Ammonaps er gunstigt ved kritisk nødvendig brug, og anbefaler, at markedsføringstilladelsen ændres, under forudsætning af at indehaveren af markedsføringstilladelsen for Ammonaps senest den 30. juni 2017 dokumenterer, at fremstillingsprocessen opfylder kravene i Kommissionens direktiv 2003/94/EF, hvad angår principperne og retningslinjerne for god fremstillingspraksis, jf. artikel 8, stk. 3, i direktiv 2001/83/EF.
• In view of the nature of the disease and the fact that alternatives are not available in all Member States;the CHMP considers Ammonaps critical to public health; The CHMP, as a consequence, considers that the benefit-risk balance of Ammonaps remains favourable for critical use and therefore recommends that the marketing authorisations be varied and subject to the condition that the marketing authorisation holder for Ammonaps provides evidence by 30 June 2017 that the manufacturing process complies with the requirements of Commission Directive
• Dutasteride Actavis bliver i øjeblikket fremstillet på et andet fremstillingssted, der er registreret i markedsføringstilladelsen
• Dutasteride Actavis is currently manufactured at an alternative manufacturing site registered in their marketing authorisation;
PII's nugældende GMP-certifikat er gyldigt til og med den 30. juni 2017.
The current certificate of GMP compliance of PII will no longer be valid after 30 June 2017.
• CHMP har i sin vurdering medtaget det restriktionsbehæftede GMP-certifikat for Pharmaceutics International Inc., som den britiske lægemiddelstyrelse udstedte den 15. juni 2016 for lægemidler, der vurderes at være kritisk nødvendige for patienterne, og som er gyldigt indtil den 30. juni 2017.
• The CHMP considered the GMP compliance certificate for Pharmaceutics International Inc. issued by the MHRA on 15th June 2016 restricted to medicinal products considered critical to public health and valid until 30 June 2017; Ammonaps
Derfor anbefaler CHMP, at markedsføringstilladelsen for Lutinus (og relaterede navne) ændres, så Pharmaceutics International Inc. fjernes fra listen over fremstillingssteder.
As a consequence, the CHMP recommends that the marketing authorisation for Lutinus (and associated names) should be varied to remove Pharmaceutical International Inc. as manufacturing site from their marketing authorisations.
Derfor anbefaler CHMP, at markedsføringstilladelsen for Dutasteride Actavis (og relaterede navne) ændres, så Pharmaceutics International Inc. fjernes fra listen over fremstillingssteder.
As a consequence, the CHMP recommends that the marketing authorisation for Dutasteride Actavis (and associated names) should be varied to remove Pharmaceutical International Inc. as manufacturing site from their marketing authorisations.
• CHMP vurderer, at de oplysninger og dokumenter, der er foreskrevet i artikel 8, stk. 3, i direktiv 2001/83/EF, er misvisende.
• The CHMP considers that at present, the particulars and documents provided for in Article 8(3) of Directive 2001/83/EC are incorrect.
Men den manglende opfyldelse af god fremstillingspraksis udgør en ikke-kvantificerbar risiko, som ikke kan afdækkes pålideligt ved hjælp af data fra brug efter markedsføringen.
However the non-compliance with good manufacturing practice presents a degree of unquantifiable risk which cannot be detected reliably through post-marketing data, hence the lack of any significant concerns cannot provide sufficient reassurance over the safety of the batches manufactured at PII.
Anvendelsen af Ammonaps-granulat bør desuden begrænses til patienter, der kræver administration gennem en næsesonde eller en gastrostomisonde, medmindre der ikke findes andre behandlingsmuligheder.
Also, unless no alternative options are available for patients, the use of Ammonaps granules should be limited to patients requiring administration through a nasogastric tube or gastrostomy.
CHMP mener derfor, at markedsføringstilladelsen for SoliCol D3 bør suspenderes, jf. artikel 116 i direktiv 2001/83/EF.
As a consequence, the CHMP is of the opinion that pursuant to Article 116 of Directive 2001/83/EC, the marketing authorisations of SoliCol D3 should be suspended.
Uanset ovenstående noterer CHMP sig erklæringen om GMP-non-compliance for PII, der blev udstedt af tilsynsmyndigheden, som anbefaler, at alle batcher af Ammonaps fra Pharmaceutics Internationals Inc. trækkes tilbage i medlemsstater, hvor produktet ikke anses for kritisk nødvendigt for den offentlige sundhed, og at der nedlægges leveringsforbud.
Notwithstanding the above, the CHMP takes note of the statement of non-compliance with GMP of PII by the Supervisory Authority which recommends that in Member States where the product is not considered critical to public health, all batches of Ammonaps from Pharmaceutics Internationals Inc. should be recalled and the supply from this manufacturing site prohibited.
Den manglende opfyldelse af god fremstillingspraksis udgør en ikke-kvantificerbar risiko, som ikke kan afdækkes pålideligt ved hjælp af data fra brug efter markedsføringen.
The non-compliance with good manufacturing practice presents a degree of unquantifiable risk which cannot be detected reliably through postmarketing data; hence the lack of any significant concerns cannot provide sufficient reassurance over the safety of the batches manufactured at PII.
• CHMP har i sin vurdering medtaget den erklæring om GMP-non-compliance for Pharmaceutics International Inc., som den britiske lægemiddelstyrelse udstedte den 15. juni 2016 med en anbefaling om, at der iværksættes restriktioner for leverancerne i EU, og at de lægemidler, der er fremstillet på dette fremstillingssted, trækkes tilbage, medmindre de vurderes at være kritisk nødvendige for patienterne
• The CHMP considered the Statement of Non-Compliance with GMP for Pharmaceutics International Inc. issued by the MHRA on 15th June 2016 recommending a restriction of supply in the EU and the recall of the medicinal products manufactured at this site unless considered critical to public health;
Hvis suspenderingen af markedsføringstilladelsen for SoliCol D3 skal kunne ophæves, skal indehaveren af markedsføringstilladelsen dokumentere, at fremstillingsprocessen opfylder kravene i Kommissionens direktiv 2003/94/EF (med ændringer), hvad angår principperne og retningslinjerne for god fremstillingspraksis, jf. artikel 8, stk. 3, i direktiv 2001/83/EF.
For the suspension of SoliCol D3 to be lifted, the marketing authorisation holder shall provide evidence that the manufacturing process complies with the requirements of Commission Directive 2003/94/EC (as amended) laying down the principles and guidelines of GMP as provided for in Article 8(3) of Directive 2001/83/EC.